Diagnosis and individual treatment of cardiovascular diseases: Targeting vascular oxidative stress

Expert Review of Clinical Pharmacology

Volumn 3, Issue 5, 2010, Pages 639-648

  Armitage, Melanie E ^a   La, Mylinh ^b   Schmidt, Harald H H W ^a,c   Wingler, Kirstin ^a,c  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b CSIRO   (Australia)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

cardiovascular diseases; individualized medicine; NADPH oxidase; nitric oxide; oxidative stress; prevention; soluble guanylate cyclase; VASP

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ARGININE; ASCORBIC ACID; AVE 9488; BAY 63 2521; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CAROTENE; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLAVONOID; GUANYLATE CYCLASE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; ISOPROSTANE; LOW DENSITY LIPOPROTEIN; NITRATE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; POLYPHENOL; REACTIVE OXYGEN METABOLITE; RENIN INHIBITOR; RIOCIGUAT; TRASTUZUMAB; UNCLASSIFIED DRUG;

BEETROOT; BLOOD VESSEL WALL; BREAST CANCER; CACAO; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; COST CONTROL; DISABILITY; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; EXERCISE; GRAPE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HIGH SODIUM INTAKE; HUMAN; HYPERTENSION; IN VITRO STUDY; LIFESTYLE; MOLECULAR IMAGING; NONHUMAN; OXIDATIVE STRESS; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PULMONARY HYPERTENSION; REPERFUSION INJURY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING; VITAMIN SUPPLEMENTATION;

EID: 77956799631     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.10.40     Document Type: Review

References (74)

1. Schulz E, Jansen T, Wenzel P, Daiber A, Munzel T. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid. Redox Signal. 10(6), 1115-1126 (2008).
2. Melichar VO, Behr-Roussel D, Zabel U et al. Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc. Natl Acad. Sci. USA 101(47), 16671-16676 (2004).
3. Vanhoutte PM. How we learned to say NO. Arterioscler. Thromb. Vasc. Biol. 29(8), 1156-1160 (2009).
4. Cobb JP. Nitric oxide synthase inhibition as therapy for sepsis: a decade of promise. Surg. Infect. (Larchmt) 2(2), 93-100 (2001).
5. Singh D, Richards D, Knowles RG et al. Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. Am. J. Respir. Crit. Care Med. 176(10), 988-993 (2007).
6. Brouckaert P, Cauwels A, Thoonen R et al. Phenotypes of sGC mutant mice in basic conditions, disease and shock. BMC Pharmacology 9(Suppl. 1), S6 (2009).
7. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 87(1), 245-313 (2007).
8. Beckman JS. Understanding peroxynitrite biochemistry and its potential for treating human diseases. Arch. Biochem. Biophys. 484(2), 114-116 (2009).
9. Böger GI, Rudolph TK, Maas R et al. Asymmetric dimethylarginine determines the improvement of endothelium-dependent vasodilation by simvastatin effect of combination with oral l-arginine. J. Am. Coll. Cardiol. 49(23), 2274-2282 (2007).
10. Foster MW, Hess DT, Stamler JS. Protein S-nitrosylation in health and disease: a current perspective. Trends Mol. Med. 15(9), 391-404 (2009).
11. Indian Polycap Study (TIPS); Yusuf S, Pais P, Afzal R. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a Phase II, double-blind, randomised trial. Lancet 373(9672), 1341-1351 (2009).
12. Couzin J. Cholesterol veers off script. Science 322(5899), 220-223 (2008).
13. Simmons RK, Alberti KG, Gale EA et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 53(4), 600-605 (2010).
14. Wang TJ, Gona P, Larson MG et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med. 355(25), 2631-2639 (2006).
15. Gerszten RE, Wang TJ. The search for new cardiovascular biomarkers. Nature 451(7181), 949-952 (2008).
16. Ray S, Britschgi M, Herbert C et al. Classification and prediction of clinical Alzheimers diagnosis based on plasma signaling proteins. Nat. Med. 13(11), 1359-1362 (2007).
17. Germano S, ODriscoll L. Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine. Curr. Cancer Drug Targets 9(3), 398-418 (2009).
18. Saga T, Koizumi M, Furukawa T, Yoshikawa K, Fujibayashi Y. Molecular imaging of cancer: evaluating characters of individual cancer by PET/SPECT imaging. Cancer Sci. 100(3), 375-381 (2009).
19. Schilsky RL. Personalized medicine in oncology: the future is now. Nat. Rev. Drug Discov. 9(5), 363-366 (2010).
20. de Klein A, van Kessel AG, Grosveld G et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300(5894), 765-767 (1982).
21. Sagara Y, Inoue Y, Kashiwagi S. Involvement of molecular mimicry between human T-cell leukemia virus type 1 gp46 and osteoprotegerin in induction of hypercalcemia. Cancer Sci. 100(3), 490-496 (2009).
22. Dotan Y, Pinchuk I, Lichtenberg D, Leshno M. Decision analysis supports the paradigm that indiscriminate supplementation of vitamin E does more harm than good. Arterioscler. Thromb. Vasc. Biol. 29(9), 1304-1309 (2009).
23. Gallicchio L, Boyd K, Matanoski G et al. Carotenoids and the risk of developing lung cancer: a systematic review. Am. J. Clin. Nutr. 88(2), 372-383 (2008).
24. Thomson L, Trujillo M, Telleri R, Radi R. Kinetics of cytochrome c2+ oxidation by peroxynitrite: implications for superoxide measurements in nitric oxide-producing biological systems. Arch. Biochem. Biophys. 319(2), 491-497 (1995).
25. Gotoh N, Niki E. Rates of interactions of superoxide with vitamin E, vitamin C and related compounds as measured by chemiluminescence. Biochim. Biophys. Acta 1115(3), 201-207 (1992).
26. Schafer ZT, Grassian AR, Song L et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461(7260), 109-113 (2009).
27. Ristow M, Zarse K. How increased oxidative stress promotes longevity and metabolic health: the concept of mitochondrial hormesis (mitohormesis). Exp. Gerontol. 45(6), 410-418 (2010).
28. Ristow M, Zarse K, Oberbach A et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc. Natl Acad. Sci. USA 106(21), 8665-8670 (2009).
29. Dotan Y, Lichtenberg D, Pinchuk I. Lipid peroxidation cannot be used as a universal criterion of oxidative stress. Prog. Lipid Res. 43(3), 200-227 (2004).
30. Halliwell B, Lee CY. Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues. Antioxid. Redox Signal. 13(2), 145-156 (2010).
31. Lambeth JD. NOX enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic. Biol. Med. 43(3), 332-347 (2007).
32. Wingler K, Wunsch S, Kreutz R, Rothermund L, Paul M, Schmidt HH. Upregulation of the vascular NAD(P)H-oxidase isoforms NOX1 and NOX4 by the renin-angiotensin system in vitro and in vivo. Free Radic. Biol. Med. 31(11), 1456-1464 (2001).
33. Guzik TJ, Chen W, Gongora MC et al. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J. Am. Coll. Cardiol. 52(22), 1803-1809 (2008).
34. McNally JS, Davis ME, Giddens DP et al. Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am. J. Physiol. Heart Circ. Physiol. 285(6), H2290-H2297 (2003).
35. Wind S, Beuerlein K, Armitage ME et al. Oxidative stress and endothelial function in aortas of SHR by NOX1/2 is reversed by NADPH oxidase inhibition. Hypertension 56(3), 490-497 (2010).
36. Kleinschnitz C, Grund H, Wingler K et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol. (2010) (In press).
37. Wind S, Beuerlein K, Eucker T et al. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br. J. Pharmacol. DOI: 10.1111/j.1476-5381.2010.00920.x (2010) (Epub ahead of print).
38. Vecchione C, Brandes RP. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ. Res. 91(2), 173-179 (2002).
39. Ignarro LJ. Nitric oxide. A novel signal transduction mechanism for transcellular communication. Hypertension 16(5), 477-483 (1990).
40. Maxwell AJ, Anderson BE, Cooke JP. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. Vasc. Med. 5(1), 11-19 (2000).
41. Bode-Boger SM, Scalera F, Ignarro LJ. The l-arginine paradox: importance of the l-arginine/asymmetrical dimethylarginine ratio. Pharmacol. Ther. 114(3), 295-306 (2007).
42. Schulman SP, Becker LC, Kass DA et al. l-arginine therapy in acute myocardial infarction: the Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 295(1), 58-64 (2006).
43. Bai Y, Sun L, Yang T, Sun K, Chen J, Hui R. Increase in fasting vascular endothelial function after short-term oral l-arginine is effective when baseline flow-mediated dilation is low: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 89(1), 77-84 (2009).
44. Leeson CP, Robinson M, Francis JM et al. Cardiovascular magnetic resonance imaging for non-invasive assessment of vascular function: validation against ultrasound. J. Cardiovasc. Magn. Reson. 8(2), 381-387 (2006).
45. Donald AE, Charakida M, Cole TJ et al. Non-invasive assessment of endothelial function: which technique? J. Am. Coll. Cardiol. 48(9), 1846-1850 (2006).
46. Maier W, Cosentino F, Lutolf RB et al. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J. Cardiovasc. Pharmacol. 35(2), 173-178 (2000).
47. Frantz S, Adamek A, Fraccarollo D et al. The eNOS enhancer AVE 9488: a novel cardioprotectant against ischemia reperfusion injury. Basic Res. Cardiol. 104(6), 773-779 (2009).
48. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug Discov. 5(9), 755-768 (2006).
49. Taylor AL, Ziesche S, Yancy C et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. 351(20), 2049-2057 (2004).
50. Munzel T, Wenzel P, Daiber A. Do we still need organic nitrates? J. Am. Coll. Cardiol. 49(12), 1296-1298 (2007).
51. Mittendorf J, Weigand S, Alonso-Alija C et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 4(5), 853-865 (2009).
52. Stasch JP, Schmidt PM, Nedvetsky PI et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J. Clin. Invest. 116(9), 2552-2561 (2006).
53. Lapp H, Mitrovic V, Franz N et al. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation 119(21), 2781-2788 (2009).
54. Weber AA, Adamzik M, Bachmann HS et al. Methods to evaluate the pharmacology of oral antiplatelet drugs. Herz 33(4), 287-296 (2008).
55. Hercberg S, Czernichow S, Galan P. Tell me what your blood b-carotene level is, I will tell you what your health risk is! The viewpoint of the SUVIMAX researchers. Ann. Nutr. Metab. 54(4), 310-312 (2009).
56. Gladwin MT, Schechter AN, Kim- Shapiro DB et al. The emerging biology of the nitrite anion. Nat. Chem. Biol. 1(6), 308-314 (2005).
57. Webb AJ, Patel N, Loukogeorgakis S et al. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension 51(3), 784-790 (2008).
58. Wink DA, Paolocci N. Mother was right: eat your vegetables and do not spit! When oral nitrate helps with high blood pressure. Hypertension 51(3), 617-619 (2008).
59. Taubert D, Roesen R, Lehmann C, Jung N, Schomig E. Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide: a randomized controlled trial. JAMA 298(1), 49-60 (2007).
60. Schmitt CA, Dirsch VM. Modulation of endothelial nitric oxide by plant-derived products. Nitric Oxide 21(2), 77-91 (2009).
61. Taubert D, Roesen R, Schomig E. Effect of cocoa and tea intake on blood pressure: a meta-analysis. Arch. Intern. Med. 167(7), 626-634 (2007).
62. Seals DR, Desouza CA, Donato AJ, Tanaka H. Habitual exercise and arterial aging. J. Appl. Physiol. 105(4), 1323-1332 (2008).
63. Adams V, Linke A, Krankel N et al. Impact of regular physical activity on the NAD(P)H Oxidase and angiotensin receptor system in patients with coronary artery disease. Circulation 111(5), 555-562 (2005).
64. Durrant JR, Seals DR, Connell ML et al. Voluntary wheel running restores endothelial function in conduit arteries of old mice: direct evidence for reduced oxidative stress, increased superoxide dismutase activity and down-regulation of NADPH oxidase. J. Physiol. 587(Pt 13), 3271-3285 (2009).
65. Orosz Z, Csiszar A, Labinskyy N et al. Cigarette smoke-induced proinflammatory alterations in the endothelial phenotype: role of NAD(P)H oxidase activation. Am. J. Physiol. Heart Circ. Physiol. 292(1), H130-H139 (2007).
66. Strazzullo P, DElia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. Br. Med. J. 339, b4567 (2009).
67. Appel LJ. Another major role for dietary sodium reduction: improving blood pressure control in patients with resistant hypertension. Hypertension 54(3), 444-446 (2009).
68. He FJ, MacGregor GA. A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. J. Hum. Hypertens. 23(6), 363-384 (2009).
69. Pimenta E, Gaddam KK, Oparil S et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 54(3), 475-481 (2009).
70. Al-Solaiman Y, Jesri A, Zhao Y, Morrow JD, Egan BM. Low-sodium DASH reduces oxidative stress and improves vascular function in salt-sensitive humans. J. Hum. Hypertens. 23(12), 826-835 (2009).
71. Ford ES, Bergmann MM, Kroger J, Schienkiewitz A, Weikert C, Boeing H. Healthy living is the best revenge: findings from the European Prospective Investigation into Cancer and Nutrition- Potsdam study. Arch. Intern. Med. 169(15), 1355-1362 (2009).
72. Woolf SH. A closer look at the economic argument for disease prevention. JAMA 301(5), 536-538 (2009).
73. Niki E. Lipid peroxidation: physiological levels and dual biological effects. Free Radic. Biol. Med. 47(5), 469-484 (2009).
74. Wingler K, Schmidt HHHW. Good stress, bad stress - the delicate balance in the vasculature. Dtsch Arztebl. Int. 106(42), 677-684 (2009).